CD274 and renal cell carcinoma: Among patients with International Metastatic RCC Database Consortium (IMDC) favorable-risk disease, only 11% (11/115) of those treated with nivolumab plus ipilimumab and 12% (13/111) of those treated with sunitinib were PD-L1+ compared to 26% (100/384) and 29% (114/392) of patients with IMDC intermediate- and poor-risk disease [8].